Advice

Following a full submission

capecitabine (Xeloda®) is accepted for use within NHS Scotland for the treatment of metastatic colorectal cancer.

The convenience of oral administration may allow changes to service delivery that have individual patient or organisational benefits, though these may be lessened when it is used in regimens whose other components require intravenous administration.

Download detailed advice102KB (PDF)

Download

Medicine details

Medicine name:
capecitabine (Xeloda)
SMC ID:
507/08
Indication:
Metastatic colorectal cancer
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
13 October 2008